Citi Maintains Buy on BioNTech (BNTX) Despite BNT113 Trial Setback

gurufocus.com · 2026-10-13

On October 13, 2026, Citi reaffirmed its Buy rating for BioNTech SE (NASDAQ: BNTX) and set a price target of $125 following the disappointing results from the B

Read the full story at gurufocus.com →